Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cogent Biosciences (COGT) Income from Continuing Operations (2017 - 2026)

Cogent Biosciences' Income from Continuing Operations history spans 10 years, with the latest figure at 97212000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations fell 35.05% to 97212000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 346967000.0 through Mar 2026, down 27.8% year-over-year, with the annual reading at 321736000.0 for FY2025, 24.78% down from the prior year.
  • Income from Continuing Operations came in at 97212000.0 for Q1 2026, down from 95305000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 31311000.0 in Q1 2022 to a low of 97212000.0 in Q1 2026.
  • The 5-year median for Income from Continuing Operations is 58347000.0 (2024), against an average of 59747176.47.
  • Year-over-year, Income from Continuing Operations plummeted 147.03% in 2022 and then fell 14.57% in 2025.
  • Cogent Biosciences' Income from Continuing Operations stood at 41635000.0 in 2022, then tumbled by 30.56% to 54358000.0 in 2023, then decreased by 28.55% to 69875000.0 in 2024, then tumbled by 36.39% to 95305000.0 in 2025, then decreased by 2.0% to 97212000.0 in 2026.
  • Per Business Quant, the three most recent readings for COGT's Income from Continuing Operations are 97212000.0 (Q1 2026), 95305000.0 (Q4 2025), and 80927000.0 (Q3 2025).